Effect of growth hormone, glutamine, and diet on body composition in short bowel syndrome: a randomized, controlled study.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The aim of this study was to assess the effect of growth hormone, glutamine, and diet on body composition.

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

A randomized, 6-week, double-blind, placebo-controlled, crossover study was performed in eight patients.

Active treatment was 21 days of growth hormone, oral glutamine, and a high-carbohydrate-low-fat (HCLF) diet.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.

In the crossover set-up each of the participants took both Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison in turn, acting as their own control.

Body composition was determined by dual-energy x-ray absorptiometry (DEXA) scan.

Treatments were compared by paired t test.

What Was Measured

Topics PubMed links to this paper include Body Composition, Dietary Carbohydrates, Dietary Fats, Glutamine, Growth Hormone and Short Bowel Syndrome.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1999 (JPEN. Journal of parenteral and enteral nutrition), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.